

PEOPLE FOR
THE ETHICAL
TREATMENT
OF ANIMALS

November 27, 2023

Matthew L. Daniel
Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief
Compliance Officer
Charles River Laboratories International, Inc.
251 Ballardvale Street
Wilmington, MA 01887

Via UPS Next Day Air Saver

Dear Mr. Daniel:

Attached to this letter is a shareholder proposal submitted for inclusion in the Charles River Laboratories International, Inc. proxy statement for the 2024 annual meeting. Also enclosed is a letter from People for the Ethical Treatment of Animals' (PETA) brokerage firm, RBC Wealth Management, confirming the requisite common stock ownership, which PETA intends to hold at least this amount through and including the date of the 2024 shareholders meeting.

PETA is available to meet in person or via teleconference within 10-30 calendar days from the date of this letter, including the following in EST:

- 12/08: 10 a.m. – 1 p.m.
- 12/20: 10 a.m. – 2 p.m.
- 12/21: 10 a.m. – 2 p.m.

If there are any issues with this proposal being included in the proxy statement or if you need any further information, please contact PETA's authorized representative Jared Goodman at 2154 W. Sunset Blvd., Los Angeles, CA 90026, +1 (323) 210-2266 or JaredG@PetaF.org.

Sincerely,

Carrie Edwards, Executive Assistant
PETA Corporate Responsibility

Enclosures: 2024 Shareholder Proposal
RBC Wealth Management letter

Washington
1536 16th St. N.W.
Washington, DC 20036
202-483-PETA

Los Angeles
2154 W. Sunset Blvd.
Los Angeles, CA 90026
323-644-PETA

Norfolk
501 Front St.
Norfolk, VA 23510
757-622-PETA

Info@peta.org
PETA.org

Entities

- PETA Asia
- PETA India
- PETA France
- PETA Australia
- PETA Germany
- PETA Switzerland
- PETA Netherlands
- PETA Foundation (U.K.)



**Wealth
Management**

November 27, 2023

Tracy Reiman
Executive Vice President
People for the Ethical Treatment of Animals
501 Front Street
Norfolk, VA 23510

Re: Verification of Shareholder Ownership in Charles River Laboratories International, Inc.

Dear Ms. Reiman,

This letter verifies that People for the Ethical Treatment of Animals Inc. (PETA) is the beneficial owner of 22 shares of Charles River Laboratories International, Inc. common stock. As of November 27, 2023, PETA holds and has held continuously for at least 3 years 13 shares of Charles River Laboratories International, Inc. common stock.

Should you have any questions or require additional information, please contact me at (408) 947-3322.

Sincerely,

A handwritten signature in black ink that reads 'Jenilee Hill'.

Jenilee Hill, APP
Senior Registered Client Associate
RBC Wealth Management

Handwritten initials 'CJH' in black ink.

Investment and insurance products offered through RBC Wealth Management are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.

Report on the Importation of Nonhuman Primates Into the U.S.

RESOLVED, that the Board shall report to shareholders annually on the species, provenance (including country of origin and wild-caught or captive-bred status), and numbers of nonhuman primates imported by our company into the U.S.; the company's procedures to screen for and report the presence of zoonotic disease among these animals; and measures taken by the company to mitigate the impact of such importation on the dwindling populations of these primates in nature, omitting proprietary information.

Supporting Statement

Our company is one of the largest importers of nonhuman primates into the U.S., bringing in thousands of monkeys each year from Southeast Asia and Mauritius. Most of them are of the species *Macaca fascicularis* (long-tailed macaque). According to the Centers for Disease Control and Prevention (CDC), 96% of the 125,099 monkeys brought into the U.S. during fiscal years 2019 to 2022 were long-tailed macaques.

In November 2022, the U.S. Department of Justice (DOJ)¹ issued indictments alleging widespread laundering of wild-caught long-tailed macaques from Cambodia as captive-bred.² On February 22, 2023, our company reported to the U.S. Securities and Exchange Commission (SEC) that the DOJ and the U.S. Fish & Wildlife Service (FWS) "had commenced an investigation into the Company's conduct regarding several shipments of non-human primates from Cambodia."³ Civil and criminal investigations are ongoing as of the date of this submission. The SEC recently announced a new investigation into our company's acquisition of monkeys from Asia.⁴ The FWS has also prevented our company from selling 1,269 monkeys to laboratories because the company couldn't prove they had been imported legally.

Imported monkeys can carry tuberculosis, deadly diarrheal pathogens, West Nile virus, malaria, herpes B, and infectious agents transmissible to humans. The CDC found that from 2019 to 2022, overall mortality in imported monkeys had doubled and the number of monkeys who were dead on arrival had quadrupled. The number of primates who entered and exited quarantine with clinical signs consistent with filovirus infection and confirmed tuberculosis, Shigella, Campylobacter, and malaria infections has increased nearly tenfold.

Despite the increase in the number of diseased monkeys being imported and our company's acknowledgement that client demand for monkeys has dropped globally by 25% in 2023,⁵ a shell company formed by some of Charles River Laboratories' top officials purchased land in Texas in order for our company to build a new monkey-importation, quarantine, and breeding facility.

¹Superseding Indictment, *U.S. v. Keo et al.* (November 3, 2022), <https://www.peta.org/wp-content/uploads/2022/11/US-v-KEO-et-al.pdf>.

²International Primatological Society. Harvesting of Wild Primates for Use in Biomedical Research, <https://www.internationalprimatologicalsociety.org/harvesting-of-wild-primates-for-use-in-biomedical-research/>.

³Charles River Laboratories. Annual Report (Form 10-K) (February 22, 2023), <https://www.sec.gov/Archives/edgar/data/1100682/000110068223000006/crl-20221231.htm>.

⁴Charles River Laboratories. Quarterly Report (Form 10-Q) (August 9, 2023), <https://www.sec.gov/Archives/edgar/data/1100682/000110068223000018/crl-20230701.htm>.

⁵Charles River Laboratories. 3Q 2023 Results (November 8, 2023), https://assets.main.pro2.maf.media-server.com/ca3e53aedca84b4e96bb4c63ed4d688b/CRL_3Q23_Earnings_Presentation_PrintVersion.pdf.

Expanding monkey-importation operations jeopardizes public health and safety and could harm Charles River's reputation and business. Transparency on these critical issues is essential for the well-being of our company.

We urge our fellow shareholders to support this responsible resolution.